Blood Vessel Articles & Analysis

https://www.termis.org/wc2018/ On September 7th, CSO speaks about monogenic disease modeling using NuHeart™ technology during TERM for heart, blood vessel & lung session. 99-O-5: Personalized micro-3D human heart tissues for orphan drug development Tetsuro Wakatsuki,Neil Daily,Pinar Kemanli, Michael Greenberg,Jennifer Strande InvivoSciences, Inc. Madison Wisconsin, USA, ...

By InvivoSciences, Inc. (IVS)

Researchers have found that increasing certain proteins in the blood vessels of mice, relaxed the vessels, lowering the animal’s blood pressure. The study provides new avenues for research that may lead to new treatments for hypertension. "The paper demonstrates that cytochrome P450 plays an important role in the management of high blood pressure, a disease of enormous public health ...

By National Institute of Environmental Health Sciences (NIEHS)

Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in equity and will support Xeltis’ clinical trial program for its XABG device, the first-ever restorative Coronary Artery Bypass Graft (CABG). XABG is a restorative, ...

By XELTIS BV

Recent research into the impact of different levels of noise on 75 volunteers reveals that disturbed sleep caused by night-time aircraft noise can damage blood vessels and increase the levels of stress hormones. As these physical changes are potential pathways to high blood pressure, heart and circulatory disease over the long term, reducing night-time aircraft noise is important for preventing ...

By European Commission, Environment DG

To learn how Xeltis’ restorative hemodialysis access graft, aXess, may be opening new horizons for patients with kidney failure, tune in the Visionary Endovascular and Vascular Education (VERVE) Symposium in Sidney, up to 4 December. In his talk on Saturday 4 December (10am AET), Professor Frans L. Moll, University Medical Center, Utrecht (NL) will explain how the Xeltis synthetic device ...

By XELTIS BV

Amsel Medical said today that it won FDA 510(k) clearance for its Amsel Endo Occluder device intended for occluding blood vessels during endoscopic procedures. The Cambridge, Mass.-based company touted that the clearance is the third the company has received from the FDA so far for its portfolio of occluder devices. The Amsel Endo Occluder is a mechanical occlusion clip delivered through a ...

By Amsel Medical Corporation

“Quantitative imaging of the airways, for example with functional respiratory imaging (FRI), is evolving from a research tool towards clinical applications” ,Dr. Maarten van den Berge, thoracic physician at the University of Groningen, states in a recently published interview. “For the past 15 years, FEV1 measurements have been the gold standard and are included in the GOLD ...

By Fluidda

Fortunately, not all brains are fleeing Italy. And when they come together the result is very often of excellence. A striking example is the TMR (registered trademark and acronym of Magnetic Resonance Therapeutic), an innovative medical device that provides great benefits for our health and well-being. The TMR is a 100% Made in Italy device, made by the Thereson company, the result of a long ...

By Thereson S.r.l.

Healionics Corporation has been awarded a $150,000 Small Business Innovation Research (SBIR) contract from the Department of Defense (DOD) to demonstrate feasibility for an improved vascular graft design. Andrew Marshall, PhD, Healionics’ Chief Technology Officer, is the Principal Investigator for this research project. Titled, “Biointegrated Synthetic Grafts for Vascular ...

By Healionics

Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells (HUCBCs) were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs. The study was published in a recent issue of ...

By Saneron CCEL Therapeutics, Inc.

Synchron, a brain computer interface (BCI) company, today announced the expansion of its advisory board comprised of industry pioneers, to provide strategic guidance in support of the Company’s clinical development plans, corporate strategy and growth. The members of the advisory board are visionaries across the technology, neuroscience and medical device industry, which include Edward ...

By Synchron, Inc.

Aidar Health, formerly known as Multisensor Diagnostics, has developed a portable hand-held device that allows patients to measure and track vital signs in a matter of seconds. Roughly the size of an iPhone, MouthLab consists of a hand unit and a mouthpiece that fits between the teeth and lips. The mouthpiece uses special sensors to gather information from breathing patterns, saliva and blood ...

By Aidar Health

It’s been a tough but very worthwhile swimming journey for our Wales and West Contracts Manager Dave Harry who recently took part in Swimathon 2015 fundraising for Ehlers-Danlos syndrome. Dave successfully swam 5KM (3 miles) and raised £455 towards ongoing research into this condition – a huge thank you to everyone that sponsored and supported Dave along the way including his ...

By Eco Environmental Services Ltd

Mercury Biomed announces that the United States Patent and Trademark Office (USPTO), after substantive examination, has issued its patent application entitled, “Altering Temperature in a Mammalian Body ” (U.S. Patent No. 9,549,844). The 844 patent, having a September 2009 priority date and exclusively licensed from the University of Texas at Austin, further expands Mercury’s ...

By Mercury Biomed

Alucent Biomedical Inc. announced that it has enrolled the first patient in ACTIVATE II, an Australia-based First-in-Human clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (AlucentNVS) technology. The therapy is designed to open vessels and maintain patency without the use of permanent implants for the treatment of peripheral artery disease ...

By Alucent Biomedical Inc.

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition characterized by increased pulmonary arterial pressure, vascular remodeling, and persistent inflammation. Despite advances in treatment, current therapies—such as sildenafil, iloprost, and riociguat—primarily focus on reducing symptoms by dilating blood vessels. Unfortunately, these therapies do ...

By SCIREQ - an emka TECHNOLOGIES Company

Concept Medical B.V. with its headquarters in Tampa, Florida has announced that on 16th October 2019, they have received the CE certification for their MagicTouch group of products. The CE certified products/brands are as listed below: MagicTouch – PTA (Sirolimus Coated PTA Balloon Catheter) for peripheral arterial disease MagicTouch – ED (Sirolimus Coated Balloon Catheter) for ...

By Concept Medical Inc.

Alucent Biomedical Inc. has received U.S. Food and Drug Administration approval to proceed with a Phase 1 clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (NVS) technology. The therapy is designed to treat peripheral artery disease (PAD) of the lower extremities, a painful and debilitating condition affecting over 200 million people worldwide. ...

By Alucent Biomedical Inc.

Alucent Biomedical Inc. announced that it has enrolled the first two patients in ACTIVATE I, a Phase 1 clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (NVS) technology. The therapy is designed to open vessels and keep them open without the use of permanent implants in the treatment of peripheral artery disease (PAD) of the lower extremities, a ...

By Alucent Biomedical Inc.

Xeltis has initiated the clinical trial for aXess, the first-ever restorative synthetic haemodialysis access graft. Several patients with kidney failure or advanced kidney disease requiring dialysis have already been successfully implanted as part of a European first-in-human trial to date. The aXess grafts enable early puncturing, or initiation of the dialysis, shortly after implanting. ...

By XELTIS BV